Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

NCT00123890 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Stopped The study was terminated due to hepatoxicity of compound

Conditions

HIV Infection

Interventions

DRUG: GW873140

Sponsor

GlaxoSmithKline